AGP Picks
View all

Retracted brain tumor papers keep getting cited, study finds

Oct. 28, 2026
Retracted brain tumor papers keep getting cited, study finds
By AI, Created 10:30 UTC, Oct 28, 2026, AGP -

A Chinese Neurosurgical Journal analysis of 582 retracted central nervous system tumor papers found that nearly 90% still received citations after retraction. The findings raise concerns about research integrity and the need for better retraction alerts in neuro-oncology.

Why it matters: - Retracted research can keep shaping later studies, clinical discussions and evidence-based care long after journals withdraw it. - The study found that 462 of 515 cited papers, or 89.71%, still received citations after retraction. - The authors say researchers need better tools and habits to check retraction status before citing papers in neuro-oncology.

What happened: - Researchers from Beijing Tiantan Hospital at Capital Medical University analyzed retracted publications on brain and central nervous system tumors. - The study appeared in Chinese Neurosurgical Journal on August 10, 2026. - The analysis covered retracted papers published between 1975 and 2025 and used records available as of December 31, 2025. - The team identified 582 retracted papers across 217 journals.

The details: - The 582 papers collected more than 12,000 citations, with a total of 12,151 citations across 515 cited papers. - Of the 217 journals, 16 each published at least 10 retracted papers and accounted for 42.61% of all retractions. - Another 30 journals lacked a 2024 impact factor, and 19 of those had been removed from major journal indexes. - Retractions peaked at 130 papers in 2023. - Papers published after 2015 made up 454 of 582 retractions, or 78.01%. - Nearly three-quarters of the retracted papers, 434 of 582, focused on gliomas, glioneuronal tumors and neuronal tumors. - Research misconduct was cited in 469 of 582 retractions, or 80.58%. - Common reasons included paper mill involvement, image duplication and compromised peer review. - China accounted for 401 of 581 papers by first author country, or 69.02%. - The United States accounted for 68 papers, or 11.70%, and India accounted for 47, or 8.09%. - Those country figures reflect retraction counts, not retraction rates, because the study did not assess total publication volume by country. - Basic research made up 438 papers, or 75.26%, while clinical research accounted for 99 papers, or 17.01%. - Among the 515 papers that were cited at least once, 182 papers, or 35.34%, received more citations after retraction than before it. - The study notes that clinicians and principal investigators should check databases such as Retraction Watch, PubMed or Web of Science before citing an article. - The paper calls for better systems to alert neuro-oncology researchers when papers are retracted. - The study’s original paper is titled "Retractions of publications on central nervous system tumors based on the Retraction Watch Database" and carries DOI 10.1186/s41016-026-00444-8. - Chinese Neurosurgical Journal is the official journal of the Chinese Neurosurgical Society and publishes neurosurgery research across clinical practice, surgical techniques and developments in neurology and neuroscience.

Between the lines: - The data suggest retraction notices are not consistently reaching the researchers who later reuse the work. - The concentration of retracted papers in a few countries and journals points to uneven quality control in parts of the publication pipeline. - The high share of misconduct-related retractions suggests this is not only a citation hygiene problem, but also a research integrity problem.

What's next: - The authors are pushing for stronger retraction alerts and more routine verification before citation. - If journals, databases and institutions improve visibility into retractions, fewer invalid findings may make it into future neuro-oncology papers. - The study adds pressure on publishers and researchers to treat retraction status as a standard part of literature review.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Beijing Free Press

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Beijing Free Press

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.